OpenLB
Open Library of Bioscience
Advanced Search
Vaccine
12 08, 2021;39 (50): 7223-7229.

Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.

Sara Suliman, Puck T Pelzer, Moagi Shaku, Virginie Rozot, Simon C Mendelsohn
Author Information
  1. Sara Suliman: Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  2. Puck T Pelzer: Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; KNCV Tuberculosis Foundation, The Hague, the Netherlands.
  3. Moagi Shaku: Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA.
  4. Virginie Rozot: Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, Wernher and Beit South Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa.
  5. Simon C Mendelsohn: Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, Wernher and Beit South Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. Electronic address: simon.mendelsohn@uct.ac.za.
PMID: 34538522 DOI: 10.1016/j.vaccine.2021.08.094

Abstract

The Global Forum on Tuberculosis (TB) Vaccines was held virtually from 20 to 22 April 2021, marking its 20 anniversary. The Global Forum on TB Vaccines is the world's largest gathering of stakeholders striving to develop new vaccines to prevent TB. The program included more than 60 speakers in 11 scientific sessions, panel discussions, and workshops. It provided an overview of the state of the field, and an opportunity to share the latest research findings, as well as new and innovative approaches to TB vaccine research and development (R&D). This year, it was held against the backdrop of the COVID-19 pandemic and convened researchers, developers, funders, and other stakeholders remotely to discuss opportunities and challenges for TB vaccine R&D in these unprecedented times.

Keywords

BCG COVID-19 Funding Pandemic Pipeline Tuberculosis Vaccine

References

  1. Cell. 2020 May 28;181(5):969-977 [PMID: 32437659]
  2. Lancet Glob Health. 2019 Dec;7(12):e1655-e1663 [PMID: 31708146]
  3. Front Immunol. 2017 Dec 15;8:1803 [PMID: 29326700]
  4. Mol Ther. 2018 Feb 7;26(2):446-455 [PMID: 29275847]
  5. Vaccine. 2013 Feb 18;31(9):1340-8 [PMID: 23290835]
  6. Cell Host Microbe. 2021 Apr 14;29(4):594-606.e6 [PMID: 33711270]
  7. AIDS. 2010 Mar 13;24(5):675-85 [PMID: 20118767]
  8. Expert Rev Vaccines. 2014 May;13(5):619-30 [PMID: 24702486]
  9. Curr Opin Immunol. 2016 Aug;41:47-54 [PMID: 27286566]
  10. Clin Infect Dis. 2014 Feb;58(4):470-80 [PMID: 24336911]
  11. EClinicalMedicine. 2020 Mar 18;21:100313 [PMID: 32382714]
  12. Lancet. 2015 Aug 29;386(9996):857-66 [PMID: 26248676]
  13. PLoS One. 2017 Jan 6;12(1):e0169539 [PMID: 28060926]
  14. N Engl J Med. 2020 Dec 31;383(27):2603-2615 [PMID: 33301246]
  15. Science. 2016 Apr 22;352(6284):aaf1098 [PMID: 27102489]
  16. J Infect Dis. 2020 Nov 13;222(12):2093-2102 [PMID: 32060529]
  17. J Clin Invest. 2018 May 1;128(5):1837-1851 [PMID: 29461976]
  18. Lancet. 2020 May 16;395(10236):1545-1546 [PMID: 32359402]
  19. Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5 [PMID: 29324233]
  20. Clin Infect Dis. 1995 Apr;20(4):982-91 [PMID: 7795103]
  21. Vaccine. 2015 Aug 7;33(33):4130-40 [PMID: 26095509]
  22. J R Soc Interface. 2013 Jul 31;10(87):20130365 [PMID: 23904584]
  23. Immunity. 2022 May 10;55(5):827-846.e10 [PMID: 35483355]
  24. EClinicalMedicine. 2020 Oct 24;28:100603 [PMID: 33134905]
  25. JAMA. 2020 Jun 9;323(22):2340-2341 [PMID: 32401274]
  26. Lancet Infect Dis. 2021 Jul;21(7):993-1003 [PMID: 33609457]
  27. Life Sci. 2020 Jul 1;252:117594 [PMID: 32305522]
  28. N Engl J Med. 2019 Dec 19;381(25):2429-2439 [PMID: 31661198]
  29. Cell Host Microbe. 2021 Jan 13;29(1):68-82.e5 [PMID: 33142108]
  30. Nat Rev Drug Discov. 2018 Apr;17(4):261-279 [PMID: 29326426]
  31. N Engl J Med. 2018 Jul 12;379(2):138-149 [PMID: 29996082]
  32. Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231 [PMID: 30092143]
  33. Health Technol Assess. 2013 Sep;17(37):1-372, v-vi [PMID: 24021245]
  34. Cell. 2018 Jan 11;172(1-2):176-190.e19 [PMID: 29328912]
  35. Tuberculosis (Edinb). 2021 Jan;126:102040 [PMID: 33310626]
  36. Cell. 2016 Oct 6;167(2):433-443.e14 [PMID: 27667685]
  37. Clin Vaccine Immunol. 2017 Feb 6;24(2): [PMID: 27974398]
  38. J Exp Med. 2015 Aug 24;212(9):1449-63 [PMID: 26282876]
  39. N Engl J Med. 2018 Oct 25;379(17):1621-1634 [PMID: 30280651]
  40. Int J Cancer. 2012 Feb 15;130(4):865-75 [PMID: 21455983]
  41. Vaccine. 2020 Oct 27;38(46):7239-7245 [PMID: 33004239]
  42. Nat Med. 2019 Jun;25(6):977-987 [PMID: 31110348]

Grants

  1. D43 TW010559/FIC NIH HHS
  2. R13 AI157206/NIAID NIH HHS

MeSH Term

COVID-19
Humans
Pandemics
SARS-CoV-2
Tuberculosis
Tuberculosis Vaccines

Chemicals

Tuberculosis Vaccines
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Congress
Article has an altmetric score of 13

Word Cloud

Created with Highcharts 10.0.0TBGlobalForumTuberculosisVaccinesheld20April2021stakeholdersnewresearchvaccineR&DCOVID-19virtually22markinganniversaryworld'slargestgatheringstrivingdevelopvaccinespreventprogramincluded60speakers11scientificsessionspaneldiscussionsworkshopsprovidedoverviewstatefieldopportunitysharelatestfindingswellinnovativeapproachesdevelopmentyearbackdroppandemicconvenedresearchersdevelopersfundersremotelydiscussopportunitieschallengesunprecedentedtimesMeetingreport:Virtual20-22BCGFundingPandemicPipelineVaccine

Similar Articles

Cited By